Drugs / Teropavimab
Teropavimab
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06031272 | May 2024 → Oct 2025 overdue | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05079451 | Jan 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT05612178 | Jul 2023 → Mar 2027 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05245292 | Dec 2022 → Dec 2025 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT04811040 | Apr 2021 → Jun 2022 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04250636 | Oct 2020 → Jan 2022 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03554408 | Jun 2018 → Feb 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03254277 | Sep 2017 → Dec 2020 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06071767 | Apr 2024 → Apr 2028 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04173819 | Jan 2019 → Sep 2023 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07820813 | Sep 2026 → Sep 2029 expected | — | Ole Schmeltz Søgaard | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05729568 | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07682961 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07683000 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT07054931 Comparator | Sep 2025 → Oct 2027 expected | HIV infectious disease | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT06205602 Comparator | Jan 2025 → Feb 2029 expected | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Recruiting | No outcome recorded |
| Phase 2 | NCT05300035 Comparator | Apr 2024 → Dec 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 2 | NCT04319367 Comparator | May 2021 → Jul 2027 expected | HIV infectious disease | Imperial College London | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-03-12 | Gilead Sciences | Results Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option gilead.com ↗
At CROI 2025, the primary results of a Phase 2 study evaluating the investigational combination of LTZ were presented during an oral session and featured in the press program; those data announced at CROI confirm previously presented Phase 1b results. |
| 2024-11-12 | Gilead Sciences | Results Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline gilead.com ↗
At Week 26, 21% (n=3) of participants who received LEN + TAB and the low dose of ZAB and 0% (n=0) participants who received LEN +TAB and the high dose of ZAB had an HIV viral load ≥50 copies/mL (per FDA Snapshot). |
| 2024-03-05 | Gilead Sciences | Results Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health gilead.com ↗
In a recent Phase 1b study published in The Lancet HIV , the investigational combination of lenacapavir + teropavimab (GS-5423, TAB) + zinlirvimab (GS-2872, ZAB) demonstrated high efficacy and maintained virologic suppression for six months with twice-yearly dosing. |
| 2023-02-22 | Gilead Sciences | Results Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV gilead.com ↗
Results fromthe Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV. |
All press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teropavimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07683000 ↗ |
| Known as | 3BNC117-LS | “Participants were randomly assigned (1:1) to receive two LS-bNAbs (3BNC117-LS and 10-1074-LS) in arm A or saline placebo in arm B” PMID 42202839 ↗ May 2026 |
| Known as | 3BNC117-LS-J | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06031272 ↗ |
| Known as | GS-5423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06071767 ↗ |
| Action | Inhibit | “can block HIV from attacking cells in the body and from spreading to other parts of the body” NCT06205602 ↗ |
| Modality | Monoclonal antibody | “The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in...” NCT03254277 ↗ |
| Route | Intravenous | “The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in...” NCT03254277 ↗ |
| Route | Subcutaneous | “The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in...” NCT03254277 ↗ |